CFD Study of Dry Pulmonary Surfactant Aerosols Deposition in Upper 17 Generations of Human Respiratory Tract

Gemci, T; Ponyavin, V; Collins, R; Corcoran, TE; Saha, SC; Islam, MS

CFD Study of Dry Pulmonary Surfactant Aerosols Deposition in Upper 17 Generations of Human Respiratory Tract

Gemci, T Ponyavin, V Collins, R Corcoran, TE Saha, SC Islam, MS

Permalink

Publisher:: MDPI
Publication Type:: Journal Article
Citation:: Atmosphere, 2022, 13, (5)
Issue Date:: 2022-05-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (2.36 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Gemci, T
dc.contributor.author	Ponyavin, V
dc.contributor.author	Collins, R
dc.contributor.author	Corcoran, TE
dc.contributor.author	Saha, SC
dc.contributor.author	Islam, MS
dc.date.accessioned	2022-08-25T04:06:12Z
dc.date.available	2022-08-25T04:06:12Z
dc.date.issued	2022-05-01
dc.identifier.citation	Atmosphere, 2022, 13, (5)
dc.identifier.issn	1598-3560
dc.identifier.issn	2073-4433
dc.identifier.uri	http://hdl.handle.net/10453/160836
dc.description.abstract	The efficient generation of high concentrations of fine-particle, pure surfactant aerosols provides the possibility of new, rapid, and effective treatment modalities for Acute Respiratory Distress Syndrome (ARDS). SUPRAER-CA™ is a patented technology by Kaer Biotherapeutics™, which is a new class of efficient aerosol drug generation and delivery system using Compressor Air (CA). SUPRAER-CA is capable of aerosolizing relatively viscous solutions or suspensions of pro-teins and surfactants and of delivering them as pure fine particle dry aerosols. In this Computational Fluid Dynamics (CFD) study, we select a number of sites within the upper 17 generations of the human respiratory tract for calculation of the deposition of dry pulmonary surfactant aerosol parti-cles. We predict the percentage of inhaled dry pulmonary surfactant aerosol arriving from the respiratory bronchioles to the terminal alveolar sacs. The dry pulmonary surfactant aerosols, with a Mass Median Aerodynamic Diameter (MMAD) of 2.6 µm and standard deviation of 1.9 µm, are injected into the respiratory tract at a dry surfactant aerosol flow rate of 163 mg/min to be used in the CFD study at an air inhalation flow rate of 44 L/min. This CFD study in the upper 17th generation of a male adult lung has shown computationally that the penetration fraction (PF) is approxi-mately 25% for the inhaled surfactant aerosols. In conclusion, an ARDS patient might receive ap-proximately one gram of inspired dry surfactant aerosol during an administration period of one hour as a possible means of further inflating partly collapsed alveoli.
dc.language	English
dc.publisher	MDPI
dc.relation.ispartof	Atmosphere
dc.relation.isbasedon	10.3390/atmos13050726
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0401 Atmospheric Sciences, 0502 Environmental Science and Management
dc.title	CFD Study of Dry Pulmonary Surfactant Aerosols Deposition in Upper 17 Generations of Human Respiratory Tract
dc.type	Journal Article
utslib.citation.volume	13
utslib.for	0401 Atmospheric Sciences
utslib.for	0502 Environmental Science and Management
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Mechanical and Mechatronic Engineering
utslib.copyright.status	open_access	*
dc.date.updated	2022-08-25T04:06:11Z
pubs.issue	5
pubs.publication-status	Published
pubs.volume	13
utslib.citation.issue	5

Abstract:

The efficient generation of high concentrations of fine-particle, pure surfactant aerosols provides the possibility of new, rapid, and effective treatment modalities for Acute Respiratory Distress Syndrome (ARDS). SUPRAER-CA™ is a patented technology by Kaer Biotherapeutics™, which is a new class of efficient aerosol drug generation and delivery system using Compressor Air (CA). SUPRAER-CA is capable of aerosolizing relatively viscous solutions or suspensions of pro-teins and surfactants and of delivering them as pure fine particle dry aerosols. In this Computational Fluid Dynamics (CFD) study, we select a number of sites within the upper 17 generations of the human respiratory tract for calculation of the deposition of dry pulmonary surfactant aerosol parti-cles. We predict the percentage of inhaled dry pulmonary surfactant aerosol arriving from the respiratory bronchioles to the terminal alveolar sacs. The dry pulmonary surfactant aerosols, with a Mass Median Aerodynamic Diameter (MMAD) of 2.6 µm and standard deviation of 1.9 µm, are injected into the respiratory tract at a dry surfactant aerosol flow rate of 163 mg/min to be used in the CFD study at an air inhalation flow rate of 44 L/min. This CFD study in the upper 17th generation of a male adult lung has shown computationally that the penetration fraction (PF) is approxi-mately 25% for the inhaled surfactant aerosols. In conclusion, an ARDS patient might receive ap-proximately one gram of inspired dry surfactant aerosol during an administration period of one hour as a possible means of further inflating partly collapsed alveoli.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/160836